CD22 and acute lymphoblastic leukemia: In contrast, approximately 80% of patients with ALL after CD19 CAR-T cell therapy had CR after CD22 CAR-T cell therapy, which was not different from patients who did not receive CD19 CAR-T cell therapy (20, 39).